Central nervous system drug disposition: The relationship between in situ brain permeability and brain free fraction

被引:220
作者
Summerfield, Scott G.
Read, Kevin
Begley, David J.
Obradovic, Tanja
Hidalgo, Ismael J.
Coggon, Sara
Lewis, Ann V.
Porter, Rod A.
Jeffrey, Phil
机构
[1] GlaxoSmithKline R&D, Dept Drug Metab & Pharmacokinet, Neurol & Gastrointestinal Ctr Excellence Drug Dis, Harlow CM19 5AW, Essex, England
[2] GlaxoSmithKline R&D, Dept Med Chem, Psychiat Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England
[3] GlaxoSmithKline R&D, Dept Drug Metab & Pharmacokinet, Psychiat Ctr Excellence Drug Discovery, Verona, Italy
[4] Kings Coll London, Pharmaceut Sci Res Div, London WC2R 2LS, England
[5] Kings Coll London, Wolfson Ctr Age Related Dis, London WC2R 2LS, England
[6] Absorpt Syst, Exton, PA USA
[7] UCB Celltech, Dept Drug Metab & Pharmacokinet, Cambridge, England
关键词
D O I
10.1124/jpet.107.121525
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The dispositions of 50 marketed central nervous system ( CNS) drugs into the brain have been examined in terms of their rat in situ ( P) and in vitro apparent membrane permeability ( P app) alongside lipophilicity and free fraction in rat brain tissue. The inter- relationship between these parameters highlights that both permeability and brain tissue binding influence the uptake of drugs into the CNS. Hydrophilic compounds characterized by low brain tissue binding display a strong correlation ( R-2 = 0.82) between P and P-app, whereas the uptake of more lipophilic compounds seems to be influenced by both P-app and brain free fraction. A nonlinear relationship is observed between logP(oct) and P over the 6 orders of magnitude range in lipophilicity studied. These findings corroborate recent reports in the literature that brain penetration is a function of both rate and extent of drug uptake into the CNS.
引用
收藏
页码:205 / 213
页数:9
相关论文
共 41 条
[31]   Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain [J].
Summerfield, SG ;
Stevens, AJ ;
Cutler, L ;
Osuna, MD ;
Hammond, B ;
Tang, SP ;
Hersey, A ;
Spalding, DJ ;
Jeffrey, P .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (03) :1282-1290
[32]  
TAKADA Y, 1992, CANCER RES, V52, P2191
[33]   AN INSITU BRAIN PERFUSION TECHNIQUE TO STUDY CEREBROVASCULAR TRANSPORT IN THE RAT [J].
TAKASATO, Y ;
RAPOPORT, SI ;
SMITH, QR .
AMERICAN JOURNAL OF PHYSIOLOGY, 1984, 247 (03) :H484-H493
[34]  
Tamai I, 2000, J PHARM SCI-US, V89, P1371, DOI 10.1002/1520-6017(200011)89:11<1371::AID-JPS1>3.0.CO
[35]  
2-D
[36]   Preface: Targeted drug delivery to the brain (blood-brain barrier, efflux, endothelium, biological transport) [J].
Terasaki, T ;
Pardridge, WM .
JOURNAL OF DRUG TARGETING, 2000, 8 (06) :353-355
[37]   Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): Insights into the mechanisms of substrate recognition [J].
Uchino, H ;
Kanai, Y ;
Kim, DK ;
Wempe, MF ;
Chairoungdua, A ;
Morimoto, E ;
Anders, MW ;
Endou, H .
MOLECULAR PHARMACOLOGY, 2002, 61 (04) :729-737
[38]   Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier [J].
Wang, Q ;
Rager, JD ;
Weinstein, K ;
Kardos, PS ;
Dobson, GL ;
Li, JB ;
Hidalgo, IJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 288 (02) :349-359
[39]  
Woods H F, 1977, Essays Neurochem Neuropharmacol, V2, P49
[40]   Flavonoid permeability across an in situ model of the blood-brain barrier [J].
Youdim, KA ;
Qaiser, MZ ;
Begley, DJ ;
Rice-Evans, CA ;
Abbott, NJ .
FREE RADICAL BIOLOGY AND MEDICINE, 2004, 36 (05) :592-604